Topics

. He can be reached at nsaraceno@mjhlifesciences.com.

Articles

An analysis conducted by RAND Corporation determines that majority of new Rx medications are first sold in the United States before making their debut in other countries. 

A Comparison of Prescription Drug Availability 

A dive into this market reveals that the latest numbers yield promising results—a global value of a worldwide $1.6 trillion—but it will continue to be attributed to past, present, and future healthcare spending. 

The Path for Prescription Drug Sales 

Health Affairs study investigates the consequences of patient medication abandonment surrounding oral HIV pre-exposure prophylaxis.

Forecasting the Effect of Out-of-Pocket Cost Changes for HIV Medication

In order to provide both profitability and medication access, a balancing act is required.

A Pharma Pricing and Agreements Primer in Today's Complex Landscape

Duplicate rebates have resulted in revenue leakage for manufacturers.

The Impact of 340B on Commercial Contracts

New England Journal of Medicine study provides a breakdown of how hospitals—especially those that qualify for discounts under the federal 340B Drug Pricing Program—are able to make a profit off insurer pharmaceutical expenditures. 

A Behind-the-Scenes Look at Drug Price Markups 

In an interview with Pharma Commerce Associate Editor Don Tracy, Ron Lanton, Partner, Lanton Law PLLC, discusses recent moves by CVS and Express Scripts to follow Mark Cuban's drug plus model.

Ron Lanton, Partner, Lanton Law PLLC, Discusses New Drug Plus Pricing Models

Experts explore ways in which the financial sector refined the healthcare landscape, including its evolutions throughout the years.

How Financialization Has Impacted the US Healthcare System

All healthcare stakeholders must participate to dismantle barriers and ensure access to medicines that save lives. 

Market Access